Latest Surrogate endpoint Stories
ROCKVILLE, Md., Feb. 9, 2015 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments.
SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S.
The FDA needs to be more effective in determining a drugâ€™s efficiency after being approved, according to a report issued on Monday by the Government Accountability Office.
Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan.
MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. today announced that a Letter to Stockholders is now posted to the Company's Web site http://www.synvista.com/.
LONDON (Reuters) - Cholesterol-lowering drugs may help to delay the progression of Alzheimer's disease, the leading cause of dementia in the elderly, French scientists said on Thursday.
- An armed gangster.